COVID-19 Research Paper Volume 14, Issue 18 pp 7193—7205

Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients


Figure 1. Humoral immune response to the Gam-COVID-Vac in 149 elderly individuals. (A) A cross-sectional study of IgG anti-RBD titers measured by ELISA in serum samples taken at 0, 14, 28, 60, 90 and 180 days’ post-vaccination (dpv). CP: SARS-CoV-2 Convalescent plasm (n = 309) analyzed with the same ELISA platform [17]. Statistical analyses were performed with Kruskal-Wallis test with two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli. ***p < 0.0001; *p < 0.05 and ns = not-significant. (B) Percentage of anti-RBD seropositive responses to the Gam-COVID-Vac vaccine in the population studied.